ganirelix acetate

Orgalutran (CA) (UK)

Pharmacologic class: Gonadotropin-releasing hormone (GnRH) antagonist

Therapeutic class: Sex hormone

Pregnancy risk category X

Action

Competitively blocks GnRH receptors on pituitary gonadotroph, suppressing secretion of gonadotropin and luteinizing hormone (LH) and thereby preventing ovulation

Availability

Prefilled syringe: 250 mcg/0.5 ml

Indications and dosages

➣ To inhibit premature LH surges during controlled ovarian hyperstimulation

Adult women: 250 mcg subcutaneously daily during early to midfollicular phase

Contraindications

• Hypersensitivity to drug, its components, GnRH, or GnRH analogs

• Known or suspected pregnancy

Precautions

Use cautiously in:

• GnRH sensitivity

• latex sensitivity (packaging contains natural rubber latex)

• breastfeeding patients.

Administration

See Know that pregnancy must be excluded before therapy begins.

• Inject into abdomen (around navel) or upper thigh.

• Be aware that drug is given with follicle-stimulating hormone (FSH). After starting FSH on day 2 or 3 of menstrual cycle, patient receives ganirelix on morning of day 7 or 8 and continues this drug until adequate follicular response occurs. Then human chorionic gonadotropin is given and FSH and ganirelix are discontinued.

Adverse reactions

CNS: headache

GI: nausea, abdominal pain of GI tract origin

GU: abdominal pain of gynecologic origin, vaginal bleeding, ovarian hyperstimulation syndrome

Other: injection site reaction, fetal death

Interactions

Drug-diagnostic tests. Hematocrit, total bilirubin: decreased values

Neutrophils: altered count (8.3/mm³ or greater)

Patient monitoring

See Monitor patient for adverse effects, especially ovarian hyperstimulation.

• Monitor total bilirubin level and CBC with white cell differential.

Patient teaching

• Inform patient about possible adverse reactions.

• Teach patient about duration of treatment and required monitoring procedures.

See Urge patient to tell prescriber if she is pregnant before starting drug.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

Anatagon

An injectable synthetic decapeptide gonadotropin-releasing hormone (GnRH) antagonist used to inhibit premature LH surges in women undergoing controlled ovarian hyperstimulation in assisted reproduction.
Adverse effects
Gynaecologic pain, foetal death, headache, ovarian hyperstimulation syndrome, vaginal bleeding.

单词	ganirelix acetate
释义	ganirelix acetate ganirelix acetate Orgalutran (CA) (UK) *Pharmacologic class:* Gonadotropin-releasing hormone (GnRH) antagonist *Therapeutic class:* Sex hormone *Pregnancy risk category X* Action Competitively blocks GnRH receptors on pituitary gonadotroph, suppressing secretion of gonadotropin and luteinizing hormone (LH) and thereby preventing ovulation Availability Prefilled syringe: 250 mcg/0.5 ml Indications and dosages ➣ To inhibit premature LH surges during controlled ovarian hyperstimulation Adult women: 250 mcg subcutaneously daily during early to midfollicular phase Contraindications • Hypersensitivity to drug, its components, GnRH, or GnRH analogs • Known or suspected pregnancy Precautions Use cautiously in: • GnRH sensitivity • latex sensitivity (packaging contains natural rubber latex) • breastfeeding patients. Administration See Know that pregnancy must be excluded before therapy begins. • Inject into abdomen (around navel) or upper thigh. • Be aware that drug is given with follicle-stimulating hormone (FSH). After starting FSH on day 2 or 3 of menstrual cycle, patient receives ganirelix on morning of day 7 or 8 and continues this drug until adequate follicular response occurs. Then human chorionic gonadotropin is given and FSH and ganirelix are discontinued. Adverse reactions CNS: headache GI: nausea, abdominal pain of GI tract origin GU: abdominal pain of gynecologic origin, vaginal bleeding, ovarian hyperstimulation syndrome Other: injection site reaction, fetal death Interactions Drug-diagnostic tests. Hematocrit, total bilirubin: decreased values Neutrophils: altered count (8.3/mm³ or greater) Patient monitoring See Monitor patient for adverse effects, especially ovarian hyperstimulation. • Monitor total bilirubin level and CBC with white cell differential. Patient teaching • Inform patient about possible adverse reactions. • Teach patient about duration of treatment and required monitoring procedures. See Urge patient to tell prescriber if she is pregnant before starting drug. • As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above. Anatagon An injectable synthetic decapeptide gonadotropin-releasing hormone (GnRH) antagonist used to inhibit premature LH surges in women undergoing controlled ovarian hyperstimulation in assisted reproduction. Adverse effects Gynaecologic pain, foetal death, headache, ovarian hyperstimulation syndrome, vaginal bleeding.
随便看	mcm2 minichromosome maintenance deficient 2, mitotin mcm3 mcm3 minichromosome maintenance deficient 3 mcm4 mcm 41 mcm4 minichromosome maintenance deficient 4 mcm5 mcm5 minichromosome maintenance deficient 5, cell division cycle 46 mcm6 mcm6 minichromosome maintenance deficient 6 mcm7 mcm7 minichromosome maintenance deficient 7 mcm8 mcm8 minichromosome maintenance deficient 8 mcm9 m-cma mcma mcmaa mcmaas mcmab mcmac mcmaf mcmahan, elizabeth anne mcmahon mcmahon and tate